Compare Crispr Therapeutics AG (CRSP) vs Cintas Corporation (CTAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Cintas Corporation — how do they compare? Crispr Therapeutics AG trades at $53.2 (market cap $4.88B), while Cintas Corporation trades at $202.27 (market cap $79.86B). The key difference: Cintas Corporation is far larger — about 16.4× Crispr Therapeutics AG's market cap, and Cintas Corporation pays a 1.03% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Cintas Corporation for 124 Days on average.
| CRSP | CTAS | |
|---|---|---|
Market Cap | $4.88B | $79.86B |
Volume | 2,861,747 | 1,323,583 |
Sector | Health | Industrials |
52-Week High | $74.92 | $216.53 |
52-Week Low | $44.34 | $163.55 |
Typical Hold Time | 77 Days | 124 Days |
Enterprise Value | $3.30B | $82.33B |
Dividend Yield | — | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
Cintas (CTAS) trades at $201.87, up 2.37% today, reflecting strong momentum after Q1 2027 earnings beat. The stock shows bullish technical signals with support near $195 and resistance at $200. Fundamentals are robust with revenue growth to $10.34B in 2025, net margin of 17.82%, and rising profitability. Recent news highlights raised guidance and record quarterly revenue exceeding $3B, signaling operational strength.
Outlook remains positive driven by organic growth and margin expansion, but high valuation multiples (P/E 39.67) pose a risk if growth slows. Analyst consensus is Moderate Buy with a $234.60 price target, implying 16% upside. Key risks include economic sensitivity and competitive pressures in uniform services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →
